Eczema & Inflammation

Trial Objective

Eczema & InflammationThe purpose of this study is to evaluate an investigational medication, INCB018424, in treating eczema, or atopic dermatitis, in children.

This topical cream belongs to a new class of medications called phosphate creams. By blocking proteins that are overactive in the skin and make eczema worse, INCB018424 may reduce inflammation. INCB018424 has been safely used in clinical studies on psoriasis, a skin condition that also is characterized by inflammation. Three different strengths of INCB018424 cream are being studied. This study is open-label, which means that the participants and their study doctor will know what strength of cream they are receiving. Participants will apply the cream twice daily.


New enrollment for this trial is temporarily paused

Who Can Participate

Participants ages 2-17 years old with atopic dermatitis covering 8 to 20% of the body.

Age: 2-17    Gender: Any Gender

Estimated Time Commitment

5 visits over 12 weeks

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Trial Coordinator, Shirley Palombi

Shirley Palombi

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Incyte Corporation

Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at